You are here: Welcome to the MPKB » Welcome to the MPKB » Non-MP therapies » Salvestrols
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:othertreatments:salvestrols [01.03.2012] – external edit 127.0.0.1home:othertreatments:salvestrols [10.20.2016] – [Curative treatments must generate immunopathology] sallieq
Line 10: Line 10:
 ===== Curative treatments must generate immunopathology ===== ===== Curative treatments must generate immunopathology =====
  
-<html><div class="mainarticle">Main section:</html> [[home:protocol:olmesartan#vitamin_d_receptor_agonist|Vitamin D Receptor agonist]] </article>+<html><div class="mainarticle">Main section:</html> [[home:protocol:olmesartan#vitamin_d_receptor_agonist|Vitamin D Receptor agonist]]
  
 According to the Marshall Pathogenesis, patients must generate immunopathology in order to recover from chronic inflammatory disease. To this end, regular dosing of olmesartan (Benicar) is critical. Olmesartan's action as a VDR agonist allows Marshall Protocol patients to activate their innate immune response. This is evident in patients taking MP antibiotics who do not begin killing bacteria until they take olmesartan. According to the Marshall Pathogenesis, patients must generate immunopathology in order to recover from chronic inflammatory disease. To this end, regular dosing of olmesartan (Benicar) is critical. Olmesartan's action as a VDR agonist allows Marshall Protocol patients to activate their innate immune response. This is evident in patients taking MP antibiotics who do not begin killing bacteria until they take olmesartan.
home/othertreatments/salvestrols.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.